bupropion was developed originally as an antidepressant - it is structurally similar to diethylpropion (an appetite suppressant)
in vitro studies suggest that bupropion is a weak inhibitor of re-uptake of dopamine and noradrenaline; also in vitro studies suggest that bupropion is, in addition, a much weaker inhibitor of serotonin re-uptake. Bupropion does not inhibit monoamine oxidase (1)
other in vitro studies suggest that bupropion acts as a non-competitive antagonist at nicotine acetylcholine receptors (2)
bupropion has a half-life of about 20 hours; steady-state plasma concentrations of bupropion and its metabolites occur within 8 days
Reference:
1) Ascher JA et al (1995). Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry, 56, 395-401.
2) Fryer JD, Lukas RJ (1999). Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine. J Pharmacol Exp Ther, 288, 88-92.
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.